cycloheximide has been researched along with pevonedistat in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Fujisaki, A; Higashiyama, S; Hiyoshi, H; Izutani, H; Joh, T; Kubota, E; Maekawa, M; Nakayama, H; Sakaue, T | 1 |
| Liu, Y; Ma, L; Meng, L; Xiong, H; Yang, Z; Zheng, D | 1 |
3 other study(ies) available for cycloheximide and pevonedistat
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Neddylated Cullin 3 is required for vascular endothelial-cadherin-mediated endothelial barrier function.
Topics: Antigens, CD; Cadherins; Capillary Permeability; Cell Communication; Cullin Proteins; Cycloheximide; Cyclopentanes; Endothelium, Vascular; Human Umbilical Vein Endothelial Cells; Humans; NEDD8 Protein; Protein Synthesis Inhibitors; Pyrimidines; RNA, Messenger; RNA, Small Interfering; Ubiquitins | 2017 |
Activation of the β‑TrCP/IκBα/inflammation axis limits the sensitivity of liver cancer cells to neddylation inhibition.
Topics: Apoptosis; beta-Transducin Repeat-Containing Proteins; Cell Line, Tumor; Cycloheximide; Cyclopentanes; Humans; Inflammation; Liver Neoplasms; NF-KappaB Inhibitor alpha; Pyrimidines; RNA, Messenger; Ubiquitin-Activating Enzymes; Ubiquitins; Xenograft Model Antitumor Assays | 2022 |